Pacific Biosciences of California Inc. [NASDAQ: PACB] surged by $1.97 during the normal trading session on Tuesday and reaching a high of $29.59 during the day while it closed the day at $29.20. The company report on July 20, 2021 that Pacific Biosciences and Invitae Announce Intent to Expand Collaboration.
Collaboration to develop production-scale HiFi Sequencing platformexpected to Include technology from Omniome, Inc.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Combining both highly accurate long and short read sequencing technologies expected to provide deeper clinical insights and lower the overall cost of analysis.
Pacific Biosciences of California Inc. stock has also loss -1.58% of its value over the past 7 days. However, PACB stock has inclined by 0.34% in the 3 months of the year. Over the past six months meanwhile, it has lost -27.36% and gained 12.57% year-on date.
The market cap for PACB stock reached $5.91 billion, with 194.79 million shares outstanding and 184.89 million shares in the current float. Compared to the average trading volume of 2.42M shares, PACB reached a trading volume of 4663304 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Pacific Biosciences of California Inc. [PACB]:
Piper Sandler have made an estimate for Pacific Biosciences of California Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on February 11, 2021. The new note on the price target was released on November 03, 2020, representing the official price target for Pacific Biosciences of California Inc. stock. Previously, the target price had yet another raise to $15, while JP Morgan analysts kept a Overweight rating on PACB stock.
The Average True Range (ATR) for Pacific Biosciences of California Inc. is set at 1.92, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 63.99. The Price to Book ratio for the last quarter was 20.28, with the Price to Cash per share for the same quarter was set at 5.74.
PACB stock trade performance evaluation
Pacific Biosciences of California Inc. [PACB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.58. With this latest performance, PACB shares gained by 0.17% in over the last four-week period, additionally sinking by -27.36% over the last 6 months – not to mention a rise of 592.76% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 46.92, with the RSI for the last a single of trading hit 45.88, and the three-weeks RSI is set at 48.16 for Pacific Biosciences of California Inc. [PACB]. The present Moving Average for the last 50 days of trading for this stock 28.48, while it was recorded at 27.49 for the last single week of trading, and 27.20 for the last 200 days.
Pacific Biosciences of California Inc. [PACB]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Pacific Biosciences of California Inc. [PACB] shares currently have an operating margin of -132.31 and a Gross Margin at +41.28. Pacific Biosciences of California Inc.’s Net Margin is presently recorded at +37.27.
Return on Total Capital for PACB is now -42.25, given the latest momentum, and Return on Invested Capital for the company is 12.51. Return on Equity for this stock inclined to 15.06, with Return on Assets sitting at 10.46. When it comes to the capital structure of this company, Pacific Biosciences of California Inc. [PACB] has a Total Debt to Total Equity ratio set at 12.52. Additionally, PACB Total Debt to Total Capital is recorded at 11.13, with Total Debt to Total Assets ending up at 10.15. Long-Term Debt to Equity for the company is recorded at 11.23, with the Long-Term Debt to Total Capital now at 9.98.
Reflecting on the efficiency of the workforce at the company, Pacific Biosciences of California Inc. [PACB] managed to generate an average of $71,367 per employee. Receivables Turnover for the company is 4.91 with a Total Asset Turnover recorded at a value of 0.28.Pacific Biosciences of California Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 35.00 and a Current Ratio set at 35.40.
Earnings per share (EPS) analysis for Pacific Biosciences of California Inc. [PACB] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc. go to -1.00%.
Pacific Biosciences of California Inc. [PACB]: Insider Ownership positions
There are presently around $4,906 million, or 83.60% of PACB stock, in the hands of institutional investors. The top three institutional holders of PACB stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 21,301,191, which is approximately -25.271% of the company’s market cap and around 1.00% of the total institutional ownership; VANGUARD GROUP INC, holding 17,766,083 shares of the stock with an approximate value of $518.77 million in PACB stocks shares; and BLACKROCK INC., currently with $481.6 million in PACB stock with ownership of nearly 9.114% of the company’s market capitalization.
Positions in Pacific Biosciences of California Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 159 institutional holders increased their position in Pacific Biosciences of California Inc. [NASDAQ:PACB] by around 23,585,076 shares. Additionally, 104 investors decreased positions by around 29,158,133 shares, while 26 investors held positions by with 115,263,025 shares. The mentioned changes placed institutional holdings at 168,006,234 shares, according to the latest SEC report filing. PACB stock had 78 new institutional investments in for a total of 7,371,939 shares, while 29 institutional investors sold positions of 5,495,811 shares during the same period.